Dr Murl Edwin Leibrecht, MD | |
578 Michael Way, Camano Island, WA 98282-8464 | |
(360) 631-5355 | |
Not Available |
Full Name | Dr Murl Edwin Leibrecht |
---|---|
Gender | Male |
Speciality | Preventive Medicine - Aerospace Medicine |
Location | 578 Michael Way, Camano Island, Washington |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1861582140 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2083A0100X | Preventive Medicine - Aerospace Medicine | MD00015522 (Washington) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Murl Edwin Leibrecht, MD 578 Michael Way, Camano Island, WA 98282-8464 Ph: (360) 631-5355 | Dr Murl Edwin Leibrecht, MD 578 Michael Way, Camano Island, WA 98282-8464 Ph: (360) 631-5355 |
News Archive
Exercise is often cited as the best preventive medicine, but how much is too much for the hearts of middle-aged athletes?
The Obama administration issued regulations yesterday addressing a top consumer gripe with health insurers: The rejected claim. "Rejection notices are often unclear, as are the procedures for challenging them." The new regulations are "designed to simplify the process and expand consumers' rights, as required by the recently enacted healthcare law." Current appeals rules differ by insurer. The regulations will standardize the process, allowing consumers to first take their complaints to the insurer, and then to an independent review panel (Levey, 7/22).
SYNthesis med chem, the global contract research organisation providing synthetic and medicinal chemistry services, today announced that the company has opened a new facility at the Babraham Research Campus in Cambridge, UK.
Offering small financial incentives doubles smoking cessation rates among socioeconomically disadvantaged smokers, according to research from The University of Texas Health Science Center at Houston.
Emergent BioSolutions Inc. today announced that it has received a multi-year grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to advance the development of MVA85A, a candidate vaccine against tuberculosis.
› Verified 5 days ago